Actinium Pharmaceuticals Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scroll to see more
Actinium Pharmaceuticals, Inc. income statement - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2018
Revenue & Gross Profit
Revenue0.000.081.031.140.000.00
Cost of Revenue0.810.000.000.000.000.00
Gross Profit-0.810.081.031.140.000.00
Operating Expenses
Research & Development30.0538.6723.1418.0316.0917.09
Selling, General & Administrative12.0813.3312.008.086.316.73
Operating Expenses42.1252.0035.1326.1122.3923.83
Operating Income-42.12-51.92-34.10-24.96-22.39-23.83
Other Income/Expense
Interest Income3.883.101.090.190.180.17
Interest Expense0.000.000.000.000.000.00
Other Income/Expense3.88-0.100.000.000.000.00
Income
Income Before Tax-38.24-48.82-33.02-24.77-22.22-23.65
Income Tax Expense0.00-1.740.000.000.000.00
Net Income-38.24-48.82-33.02-24.77-22.22-23.65
Net Income - Continuous Operations-38.24-48.82-33.02-24.770.000.00
Net Income - Discontinued Operations0.000.000.000.000.000.00
EBITDA-41.91-51.71-33.90-24.78-22.26-23.78
EBIT-42.12-51.92-34.10-24.96-22.39-23.83
Depreciation & Amortization0.210.210.210.190.140.00
Earnings Per Share
Basic EPS-1.00-2.00-1.00-1.00-2.00-7.00
Diluted EPS-1.00-2.00-1.00-1.00-2.00-7.00
Basic Shares Outstanding30.0726.6024.1420.5712.133.53
Diluted Shares Outstanding30.0726.6024.1420.5712.133.53